Advanced

Soluble HER3 predicts survival in bladder cancer patients

Memon, Ashfaque A. LU ; Gilliver, Stephen C.; Borre, Michael; Sundquist, Jan LU ; Sundquist, Kristina LU ; Nexo, Ebba and Sorensen, Boe S. (2018) In Oncology Letters 15(2). p.1783-1788
Abstract

The role of soluble human epidermal growth factor receptor (sHER3) in bladder cancer remains unclear. In the present study, an ELISA was developed for the quantification of sHER3 and its role was investigated in patients with bladder cancer (n=82) followed for 10 years. Furthermore, the effects of sHER3 on bladder cancer cell growth and migration were also investigated. The results demonstrated that plasma sHER3 levels were significantly higher in non-invasive tumours (Ta) compared with muscle-invasive tumours (T2-T4). Higher sHER3 levels were associated with a more improved survival rate. However multivariate Cox regression analysis, adjusted for clinical stage, grade, type and size of the tumour, demonstrated that sHER3 was not an... (More)

The role of soluble human epidermal growth factor receptor (sHER3) in bladder cancer remains unclear. In the present study, an ELISA was developed for the quantification of sHER3 and its role was investigated in patients with bladder cancer (n=82) followed for 10 years. Furthermore, the effects of sHER3 on bladder cancer cell growth and migration were also investigated. The results demonstrated that plasma sHER3 levels were significantly higher in non-invasive tumours (Ta) compared with muscle-invasive tumours (T2-T4). Higher sHER3 levels were associated with a more improved survival rate. However multivariate Cox regression analysis, adjusted for clinical stage, grade, type and size of the tumour, demonstrated that sHER3 was not an independent biomarker of survival. Exogenous sHER3 significantly inhibited bladder cancer cell growth and migration. These results suggest that high sHER3 levels are associated with improved survival rates in patients with bladder cancer, and that sHER3 inhibits bladder cancer cell growth and migration.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Bladder cancer, ErbB3, Human epidermal growth factor receptor3, Soluble human epidermal growth factor receptor3, Survival
in
Oncology Letters
volume
15
issue
2
pages
6 pages
publisher
Spandidos Publications
external identifiers
  • scopus:85038423415
ISSN
1792-1074
DOI
language
English
LU publication?
yes
id
778e1406-73e3-4be2-9d9f-7ec9daec7860
date added to LUP
2018-01-02 11:50:28
date last changed
2018-05-29 09:50:05
@article{778e1406-73e3-4be2-9d9f-7ec9daec7860,
  abstract     = {<p>The role of soluble human epidermal growth factor receptor (sHER3) in bladder cancer remains unclear. In the present study, an ELISA was developed for the quantification of sHER3 and its role was investigated in patients with bladder cancer (n=82) followed for 10 years. Furthermore, the effects of sHER3 on bladder cancer cell growth and migration were also investigated. The results demonstrated that plasma sHER3 levels were significantly higher in non-invasive tumours (Ta) compared with muscle-invasive tumours (T2-T4). Higher sHER3 levels were associated with a more improved survival rate. However multivariate Cox regression analysis, adjusted for clinical stage, grade, type and size of the tumour, demonstrated that sHER3 was not an independent biomarker of survival. Exogenous sHER3 significantly inhibited bladder cancer cell growth and migration. These results suggest that high sHER3 levels are associated with improved survival rates in patients with bladder cancer, and that sHER3 inhibits bladder cancer cell growth and migration.</p>},
  author       = {Memon, Ashfaque A. and Gilliver, Stephen C. and Borre, Michael and Sundquist, Jan and Sundquist, Kristina and Nexo, Ebba and Sorensen, Boe S.},
  issn         = {1792-1074},
  keyword      = {Bladder cancer,ErbB3,Human epidermal growth factor receptor3,Soluble human epidermal growth factor receptor3,Survival},
  language     = {eng},
  month        = {02},
  number       = {2},
  pages        = {1783--1788},
  publisher    = {Spandidos Publications},
  series       = {Oncology Letters},
  title        = {Soluble HER3 predicts survival in bladder cancer patients},
  url          = {http://dx.doi.org/},
  volume       = {15},
  year         = {2018},
}